BioSpace News Archive

ECP Pharma is a global company with operations in the United States, Canada, and Latin America that is committed to research, development & manufacturing of innovative drug products that enhance human life.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the successful closing of an equity investment totaling EUR 33 million from the Indigenous Critical Infrastructure Fund Canada and from a private equity fund managed by Portland Investment Counsel Inc., a related and connected party to Portland Holdings.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that the Company will give a presentation at the 2022 Stifel CNS Days on Tuesday, March 29, 2022 at 4:00pm ET.

Pfizer Inc. announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™, to 95 low- and middle-income countries, pending authorization or approval.

First Wave BioPharma, Inc. announced that James Sapirstein, Chairman and Chief Executive Officer, will deliver a virtual presentation at Maxim’s 2022 Virtual Growth Conference being held March 28 – 30, 2022.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), today announced that the first patient has been dosed in the potentially registrational Phase 1/2 trial of ZN-d5, the Company’s oral selective BCL-2 inhibitor candidate for hematologic malignances and related disorders, in patients with relapsed or refractory light chain (AL) amyloidosis.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, President and Chief Executive Officer of Tonix Pharmaceuticals, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

Cyclacel Pharmaceuticals, Inc. will announce fourth quarter and full year 2021 financial results on Monday, March 28, 2022.

Ribon Therapeutics today announced that it initiated the healthy volunteer portion of its Phase 1, first-in-human, single ascending dose and multiple ascending dose (SAD/MAD) safety and pharmacokinetic study of RBN-3143.

KalVista Announces Publication of Additional KVD900 Data in Clinical & Experimental Allergy.